News DexCom, Inc.

Stocks

DXCM

US2521311074

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-15 EDT			5-day change	1st Jan Change
72.73 ^USD	-1.88%		-1.14%	+9.58%

07-15	Mizuho Adjusts Price Target on DexCom to $90 From $85, Maintains Outperform Rating	MT
07-13	DexCom's G7 Glucose Monitor Receives Health Canada Authorization for Adults With Diabetes	MT

All News

Mentions Relevance

07-15	Mizuho Adjusts Price Target on DexCom to $90 From $85, Maintains Outperform Rating	MT
07-13	DexCom's G7 Glucose Monitor Receives Health Canada Authorization for Adults With Diabetes	MT
07-13	Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes	PU
07-13	DexCom, Inc. Announces Health Canada Authorization For Dexcom G7 15 Day Continuous Glucose Monitoring System	CI
07-09	Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time	BU
07-03	Dexcom Recalls Certain Lots of Dexcom G7 Continuous Glucose Monitoring System Sensors	CI
07-03	Alert from law firm on Dexcom withdrawn	RE
07-03	Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?	PR
06-23	Dexcom Further Advances Vision of Glucose Biosensing for All	BU
06-23	Deutsche Bank Initiates Coverage on DexCom With Buy Rating, $86 Price Target	MT
06-16	AI Can Play 'Significant' Role in Tech for Managing Diabetes, Says David Roman	MT
06-15	Piper Sandler Adjusts Price Target on DexCom to $88 From $75, Maintains Overweight Rating	MT
06-12	Dexcom Inc Clears First Over-The-Counter Continuous Glucose Monitor For Children	CI
06-12	FDA clears first over-the-counter glucose monitor for children	RE
06-11	Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction	RE
06-10	TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating	MT
06-09	Raymond James Adjusts Price Target on DexCom to $91 From $81, Maintains Strong Buy Rating	MT
06-08	Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating	MT
06-06	Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin	BU
06-06	Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study	RE
06-06	DexCom, Inc. Announces Results From CONNECT Randomized Controlled Trial Demonstrating Use Of Dexcom G7 Leads To Clinically And Statistically Significant Reduction In A1C And Improvement In Glucose Control Among People With Type 2 Diabetes Not Using Insulin	CI
06-05	Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating	MT
06-04	Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026	BU
06-04	DexCom Presents Results from The CONNECT Randomized Control Trial, Launches Reimagined Stelo Ap	CI
06-02	Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience	BU